Reuters logo
BRIEF-Amgen says new Repatha analysis demonstrates cardiovascular outcomes efficacy
August 28, 2017 / 12:51 PM / a month ago

BRIEF-Amgen says new Repatha analysis demonstrates cardiovascular outcomes efficacy

Aug 28 (Reuters) - Amgen Inc

* New repatha® (evolocumab) analysis demonstrates cardiovascular outcomes efficacy and safety of achieving very low ldl-c levels

* Amgen- ‍analysis demonstrated there was highly significant progressive relationship between lower ldl-c and a lower risk of primary composite endpoint​

* Amgen inc - ‍no new safety concerns were identified in this large clinical trial with roughly 60,000 patient-years of follow-up​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below